

## **AGENDA**

## MDUK Oxford Neuromuscular Centre Annual Meeting

Wednesday 26<sup>th</sup> March 2025 L2. Mathematical Institute. University of Oxford

L2, Mathematical Institute, University of Oxford	
08:00 - 08:30	Registration, Tea, & Pastries
Session 1: Future plans for the MDUK Oxford Neuromuscular Centre	
08:30 - 09:20	Welcome from the Director Prof Matthew Wood, Dept of Paediatrics, University of Oxford
	Early diagnosis and pre-symptomatic treatment in DMD Prof Laurent Servais, Dept of Paediatrics, University of Oxford
Session 2: DMD diagnosis and evaluation – Chair: Prof Dame Kay Davies	
09:20 - 10:40	Newborn screening for DMD: milestones and remaining challenges Prof Emma Ciafaloni, University of Rochester Medical Center
	Stride velocity 95 <sup>th</sup> centile (SV95C) in children with DMD (title TBD)  Damien Eggenspieler, SYSNAV Healthcare
	Access to treatments: what we should all be thinking about from diagnosis and beyond Emily Reuben, <i>Duchenne UK</i>
10:40 - 11:00	Tea & Coffee
Session 3: DMD therapies – Chair: Prof Laurent Servais	
	<b>DMD therapies (title TBD)</b> Prof Richard Finkel, St Jude Children's Research Hospital
11:00 - 12:30	Industry perspective on early interventional therapies in DMD  Panel members: Dr Steve Hughes (Avidity Biosciences), Dr Ashish Dugar (Dyne Therapeutics), Dr Steve Han (PepGen), Dr Shabir Hasham (Santhera Pharmaceuticals), Dr Suki Malhi (Wave Life Sciences), and Dr Rachel Salazar (Sarepta Therapeutics)
12:30 - 13:30	Lunch
Session 4: Motor Neurone Disease – Chair: Prof Martin Turner	
13:30 - 15:20	Studying pre-symptomatic populations at risk of ALS  Dr Alex Thompson, Nuffield Dept of Clinical Neurosciences, University of Oxford
	<b>Experimental medicine approaches to ALS treatments</b> Prof Kevin Talbot, <i>Nuffield Dept of Clinical Neurosciences, University of Oxford</i>
	Diamoukous of tweetment vernouse in antisouse clisenvelectide (Teferson) studies in ALC

Dr Carrie Rubel, Biogen

Prof Pietro Fratta, University College London

Biomarkers of treatment response in antisense oligonucleotide (Tofersen) studies in ALS

Creation of de novo cryptic splicing for ALS and FTD precision medicine



15:20 15:40 Tea & Coffee

17:00

15:40

Session 5: Featured Centre projects – Chair: Dr Sithara Ramdas

**Expanding the CRISPR toolkit for neuromuscular disease** 

Prof Carlo Rinaldi, Dept of Paediatrics, University of Oxford

Using immunoassays to unravel the inflammatory neuropathies

A/Prof Simon Rinaldi, Nuffield Dept of Clinical Neurosciences, University of Oxford

Myasthenia gravis - changes in demographics, features and management over the last

decades

A/Prof Isabel Leite, Nuffield Dept of Clinical Neurosciences, University of Oxford

Wrap-up and closing

Dr Sithara Ramdas, Oxford University Hospitals

17:00 18:00 **Posters & Drinks Reception** 

## Thank you to our industry sponsors

